Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum

  • Cosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) disease spectrum
     
  • There are approximately 1.7 million patients with nr-axSpA in the top five EU countries and US1
     
  • Cosentyx is also approved for the treatment of moderate-to-severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)2-4
      …
/by